Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Clinical trial NCT04199689 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04199689
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-27
- Primary completion
- 2027-08-27
- Enrollment
- 6033
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.